{"id":"smallpox-vaccine-cj-50300","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108688","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine uses a modified vaccinia virus vector expressing smallpox antigens to stimulate both cellular and humoral immunity. This approach aims to provide protective immunity against smallpox while potentially offering improved safety and immunogenicity compared to traditional live vaccine platforms. The recombinant design allows for controlled antigen presentation and reduced reactogenicity.","oneSentence":"CJ-50300 is a recombinant vaccinia virus-based vaccine designed to induce immune responses against smallpox virus antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:08.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smallpox prevention and immunization"}]},"trialDetails":[{"nctId":"NCT01056770","phase":"PHASE3","title":"Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-10","conditions":"Smallpox","enrollment":88},{"nctId":"NCT00607243","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of CJ-50300 in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-01","conditions":"Smallpox","enrollment":123},{"nctId":"NCT01317238","phase":"PHASE3","title":"Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-10","conditions":"Smallpox","enrollment":145},{"nctId":"NCT00336635","phase":"PHASE1","title":"Safety and Immunogenicity of CJ-50300","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2006-06","conditions":"Smallpox","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CJ-53300"],"phase":"phase_3","status":"active","brandName":"smallpox vaccine CJ-50300","genericName":"smallpox vaccine CJ-50300","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CJ-50300 is a recombinant vaccinia virus-based vaccine designed to induce immune responses against smallpox virus antigens. Used for Smallpox prevention and immunization.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}